DEBRA CURTIS: Open Payments
NPI 1083729065 · CATONSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,039 in 46 payments from 14 companies in 2025. Trend: 2023 $1,319 · 2024 $1,129 · 2025 $1,039
Food & beverage: $1,039
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $162 |
| Astellas Pharma US Inc | 6 | $160 |
| PFIZER INC. | 5 | $114 |
| ABBVIE INC. | 5 | $107 |
| Lilly USA, LLC | 4 | $87 |
| Merck Sharp & Dohme LLC | 3 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $60 |
| Amgen Inc. | 2 | $43 |
Products named: Veozah, Ozempic, JARDIANCE, GEMTESA, NURTEC ODT, GARDASIL 9, Kerendia, VRAYLAR.
Industry payments across MD — which companies pay providers there.
